Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab + Olaparib in BRCA1/2 and PALB2-Associated Metastatic HER2-negative Breast Cancer
NCT06488378Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axatilimab in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 4 weeks. Started Aug 2024; status: recruiting.
02
Drugs
axatilimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06488378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488378.